Acute MDPV Binge Paradigm on Mice Emotional Behavior and Glial Signature
Mafalda Campeão1, Luciana Fernandes1, Inês R Pita1
1Institute of Pharmacology and Experimental Therapeutics/IBILI, Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal.
Abstract:
3,4-Methylenedioxypyrovalerone (MDPV), a widely available synthetic cathinone, is a popular substitute for classical controlled drugs of abuse, such as methamphetamine (METH). Although MDPV poses public health risks, its neuropharmacological profile remains poorly explored. This study aimed to provide evidence on that direction. Accordingly, C57BL/6J mice were exposed to a binge MDPV or METH regimen (four intraperitoneal injections every 2 h, 10 mg/kg). Locomotor, exploratory, and emotional behavior, in addition to striatal neurotoxicity and glial signature, were assessed within 18-24 h, a known time-window encompassing classical amphetamine dopaminergic neurotoxicity. MDPV resulted in unchanged locomotor activity (open field test) and emotional behavior (elevated plus maze, splash test, tail suspension test). Additionally, striatal TH (METH neurotoxicity hallmark), Iba-1 (microglia), GFAP (astrocyte), RAGE, and TLR2/4/7 (immune modulators) protein densities remained unchanged after MDPV-exposure. Expectedly, and in sheer contrast with MDPV, METH resulted in decrease general locomotor activity paralleled by a significant striatal TH depletion, astrogliosis, and microglia arborization alterations (Sholl analysis). This comparative study newly highlights that binge MDPV-exposure comes without evident behavioral, neurochemical, and glial changes at a time-point where METH-induced striatal neurotoxicity is clearly evident. Nevertheless, neuropharmacological MDPV signature needs further profiling at different time-points, regimens, and brain regions.
Insights
Binge exposure to 3,4-Methylenedioxypyrovalerone (MDPV) did not cause behavioral or neurotoxic effects in mice. Unlike methamphetamine (METH), MDPV showed no impact on locomotor activity, emotional behavior, or striatal neurochemistry.
Area of Science:
- Neuropharmacology
- Toxicology
- Behavioral Neuroscience
Background:
- 3,4-Methylenedioxypyrovalerone (MDPV) is a synthetic cathinone frequently used as a substitute for controlled substances like methamphetamine (METH).
- Despite public health concerns, the neuropharmacological effects and potential neurotoxicity of MDPV are not well understood.
- This study investigates the comparative neuropharmacological profile of MDPV and METH.
Purpose of the Study:
- To compare the neurochemical and behavioral effects of binge MDPV exposure with those of METH.
- To assess potential striatal neurotoxicity and glial activation following MDPV administration.
- To elucidate the neuropharmacological signature of MDPV in a preclinical model.
Main Methods:
- C57BL/6J mice received binge regimens of MDPV or METH (10 mg/kg, i.p., four injections every 2 h).
- Locomotor activity, emotional behavior (elevated plus maze, splash test, tail suspension test), striatal tyrosine hydroxylase (TH) levels, and glial markers (Iba-1, GFAP) were assessed.
- Immune modulators (RAGE, TLR2/4/7) and microglia morphology (Sholl analysis) were also evaluated.
Main Results:
- MDPV exposure did not alter locomotor activity or emotional behaviors.
- Striatal TH levels, a marker for dopaminergic neurotoxicity, remained unchanged after MDPV administration.
- In contrast, METH exposure significantly reduced locomotor activity and depleted striatal TH, alongside inducing astrogliosis and altering microglia morphology.
Conclusions:
- Binge MDPV exposure at the tested dose and time-point does not induce evident behavioral, neurochemical, or glial changes.
- These findings contrast sharply with METH, which clearly demonstrated striatal neurotoxicity and associated behavioral alterations.
- Further research is warranted to fully characterize the neuropharmacological profile of MDPV across different dosages, time-points, and brain regions.
